Medivation price target raised to $101 from $85 at JPMorgan

theflyonthewall.com

JPMorgan raised its price target for Medivation (MDVN) shares to $101 citing the robust phase 3 PREVAIL data of Xtandi. The firm believes the efficacy metrics strongly favor Medivation's Xtandi to Johnson & Johnson's (JNJ) Zytiga. JPMorgan keeps an Overweight rating on Medivation.

View Comments (0)